Last mentioned: Mar 24, 2026
Brazil Patent Grant
Recce Pharmaceuticals officially receives patent grant from the Brazilian National Institute of Industrial Property (INPI).
Clinical Expansion
Recce expands Phase II clinical trials for RECCE® 327 in topical and intravenous applications.
US Patent Milestone
Recce secures key composition of matter patents in the United States, strengthening its North American position.
Recce Pharmaceuticals has been granted a critical patent in Brazil for its synthetic anti-infective platform, marking a significant expansion into South America's largest healthcare market. The patent protects the composition and manufacturing of its lead candidates, RECCE® 327 and RECCE® 529, as the company targets the global antimicrobial resistance crisis.
This page surfaces every story mentioning Recce Pharmaceuticals Ltd across our legal coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running legal beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Recce Pharmaceuticals Ltd was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |